Valuation: StemRIM

Market Cap 18.68B 117M 102M 94.84M 87.08M 164M 11.19B 167M 1.12B 439M 5.57B 440M 431M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 73.33M 63.74M 59.33M 54.47M 103M 7B 104M 699M 274M 3.48B 275M 269M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
49.63%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 30/09/2022
Chief Executive Officer 58 24/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 31/01/2007
Director/Board Member 58 28/02/2019
Director/Board Member 54 30/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 114M
+3.29%+16.98%+37.51%+2.22% 75.12B
+2.72%-8.27%+20.23%+179.60% 47.63B
-2.75%+48.50%+48.50%+48.50% 49.48B
-3.81%+6.32%-54.61%-53.87% 42.95B
-2.40%+1.16%+60.26%-23.48% 30.72B
-2.82%+2.43%+54.12%+89.44% 24.93B
-5.35%-3.86%+70.51%-53.80% 22.98B
-1.59%-4.78%-11.93%+136.89% 19.56B
-0.42%+2.66%+68.31%+128.45% 17.19B
Average -1.31%+2.60%+32.54%+50.44% 36.73B
Weighted average by Cap. -0.69%+3.33%+29.04%+42.24%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.69M -11.03M -10.27M -9.43M -17.8M -1.21B -18.08M -121M -47.5M -603M -47.65M -46.61M -1.93B -12.1M -10.52M -9.79M -8.99M -16.98M -1.16B -17.24M -115M -45.31M -575M -45.46M -44.46M
Net Debt -8.41B -52.77M -45.88M -42.7M -39.21M -74.04M -5.04B -75.18M -503M -198M -2.51B -198M -194M -6.99B -43.89M -38.15M -35.51M -32.6M -61.57M -4.19B -62.52M -419M -164M -2.09B -165M -161M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
45
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B